Skip to content Skip to sidebar Skip to footer
Menu
Menu
Newsletter
Menu
Newsletter
Paradigm Biopharmaceuticals
Healthcare Stocks
Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something to say about that. You see, any ‘treatments’ that exist are only about addressing the pain or other symptoms rather than being a cure or remission. These treatments tend to need frequent administration or lose effectiveness…
September 6, 20240Comments
Cann Group
Agriculture Stocks Cannabis Stocks Healthcare Stocks Mid Cap Stocks Small Caps Stocks
Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017
Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian Government's Office of Drug Control in March 2017. During this time, there have been various busts and booms in the cannabis sector, although there has been little hype since the aftermath of TGA's declassification of certain…
September 6, 20240Comments
Percheron Therapeutics
Healthcare Stocks
Percheron Therapeutics (ASX:PER): Releasing Phase II data by the end of CY24, and successful data could lead to a major re-rate
It has been less then a year since Antisense Therapeutics changed its name to Percheron Therapeutics (ASX:PER). It is common for biotech companies to change their name when they pivot to new indications and/or to new assets, but this was not the case with Percheron. It is still focused on Duchenne Muscular Dystrophy (DMD), a…
September 3, 20240Comments
Qantas' capex
Airlines
Qantas’ capex bill: The company is coping with a $12bn+ bullet for now, but will it eventually bite shareholders?
Qantas' capex needs are bubbling under the surface, but have not gone away. Former CEO Alan Joyce's tenure came to an unceremonious end last year. There have been many criticisms of his tenure including centralisation of decision-making around himself, his using of the airline for social causes and relations with employees, both mainline staff and…
September 2, 20240Comments
Proteomics International Laboratories
Healthcare Stocks
Proteomics International Laboratories (ASX:PIQ): It thinks its got a great DKD detection test, but do regulators agree?
Proteomics International Laboratories (ASX:PIQ) is one of the larger companies that will be presenting at next month's Life Sciences Conference. Capped at over $100m, its flagship product is PromarkerD, a predictive test for Diabetic Kidney Disease (DKD). Like all up and coming healthcare stocks, it has a great idea, but execution is the key. And…
August 28, 20240Comments
Monkeypox stocks
Healthcare Stocks
Here are 5 Monkeypox stocks to consider as the fight against the epidemic continues
Monkeypox stocks have enjoyed a good run in the last few weeks, with the World Health Organisation (WHO) classifying Monkeypox as a 'public health emergency of international concern'. Moneykpox is a virus that is spread through direct contact with infected liasons, bodily fluids or contaminated materials like bedding. It causes flu-like symptoms and skin blisters across…
August 26, 20240Comments
milestones of ASX biotech companies
Healthcare Stocks
Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval
The list of major milestones of ASX biotech companies is headed with clinical trial results, regulatory approval and commercialisation. However, clinical trials can take a long time, and there are no guarantees of success. And, as goes without saying, there won't be regulatory approval or commercialisation without results. As important as they are, there are other…
August 23, 20240Comments
Recce Pharmaceuticals investors
Healthcare Stocks
Recce Pharmaceuticals investors are excited despite the market volatility – and there’s good reason
Recce Pharmaceuticals investors are amongst the few investors in ASX stocks that have a reason to smile right now. Their company has significantly outperformed the broader ASX, sitting in positive territory while the rest of the market has been volatile. Although there weren't any announcements out of Recce - other than the completion of its Share…
August 22, 20240Comments

the Kick-ass Multipurpose WordPress Theme

Investing in the Year of the Rat
2020, the Golden Year
Market trouble spots to avoid in 2020
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here